Quick Search:

is currently disabled due to reindexing of the ZORA database. Please use Advanced Search.
uzh logo
Browse by:
bullet
bullet
bullet
bullet

Zurich Open Repository and Archive 

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-36617

Steffel, J; Akhmedov, A; Fahndrich, C; Ruschitzka, F; Luscher, T F; Tanner, F C (2006). Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells. Biochemical and Biophysical Research Communications (BBRC), 349(2):597-603.

[img] PDF - Registered users only
2MB

Abstract

In endothelial cells (EC), celecoxib inhibits expression of tissue factor (TF), a key protein for initiation and propagation of thrombus formation. The current study was designed to examine the effect of celecoxib on TF expression and activity in VSMC. In contrast to EC, celecoxib increased TNF-alpha-induced TF expression and surface activity in VSMC by 33% and 20%, respectively, as compared to TNF-alpha alone, while rofecoxib or NS-398 had no effect. Celecoxib increased p38 MAP kinase (p38), p44/42 MAP kinase (ERK), and p70S6 kinase (p70S6K) phosphorylation while leaving JNK activation unaffected. Simultaneous inhibition of p38 and ERK reduced TNF-alpha-induced TF expression by 59%, while inhibition of JNK with SP600125 did not affect TF expression. Thus, in contrast to endothelial cells, celecoxib does not inhibit TF expression in VSMC, but instead enhances it. As neither rofecoxib nor NS-398 affected TF expression, this effect does not seem to be related to COX-2 inhibition but rather appears to be mediated by an increase in p38, ERK, and p70S6K activation. The observation that the inhibiting effect of celecoxib on endothelial TF expression does not extend to VSMC may have important implications for patients with cardiovascular disease.

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiology
DDC:610 Medicine & health
Uncontrolled Keywords:Anti-Inflammatory Agents, Non-Steroidal/*pharmacology;Atherosclerosis/pathology;Cell Line;Endothelium, Vascular/*drug effects/metabolism;*Gene Expression Regulation;Heart Diseases/pathology;Humans;Lactones/pharmacology;Muscle, Smooth, Vascular/*drug effects/metabolism;Pyrazoles/*pharmacology;Sulfonamides/*pharmacology;Sulfones/pharmacology;Thromboplastin/*biosynthesis;Thrombosis/pathology;Transcription, Genetic/drug effects;Tumor Necrosis Factor-alpha/metabolism
Date:2006
Deposited On:22 Feb 2011 15:29
Last Modified:23 Nov 2012 15:08
Publisher:Elsevier
ISSN:0006-291X
Publisher DOI:10.1016/j.bbrc.2006.08.075
PubMed ID:16949034
Citations:Google Scholar™
Scopus®. Citation Count: 5

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page